Phase 3 trials currently underway Seven TRIUMPH trials are testing retatrutide across multiple indications: TRIUMPH-1 : Obesity without diabetes TRIUMPH-2 : Type 2 diabetes TRIUMPH-3 : Obesity with type 2 diabetes TRIUMPH-4 : Obesity with knee osteoarthritis (COMPLETED, 28.7% weight loss) TRIUMPH-5 : Obstructive sleep apnea TRIUMPH-6 and 7 : Additional indications These trials will provide the definitive data for the commercial dosage chart
[5] To address supply-chain quality, the FDA established import alert 66-80, which allows the agency to stop GLP-1 active pharmaceutical ingredients from entering the United States when there are signals of poor quality or unverified sourcing
Because of this, its long-term safety and actual effectiveness in humans remain unproven, and many experts warn that the benefits seen in labs may not translate perfectly to the human body
Brain Activity fMRI scans reveal heightened activity in reward centers (e.g., striatum) and reduced activity in impulse-control regions (e.g., prefrontal cortex) in those with obesity, creating a double whammy for food noise
J., Christensen, D., Kurzius-Spencer, M
